Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.42 |
| ▸ | OXTR | P30559 | 5/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200269 | 0.91 | KDM4D (0.42) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19183091 | 0.89 | KDM4D (0.41) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200952 | 0.89 | KDM4D (0.41) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200374 | 0.88 | KDM4D (0.40) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200950 | 0.88 | OXTR (0.37) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200379 | 0.88 | GRM7 (0.46) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200378 | 0.88 | GRM7 (0.46) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200313 | 0.88 | OXTR (0.40) | OXTRGRM7CYP3A4AVPR2AVPR1A | |
| SCHEMBL19183522 | 0.87 | KDM4D (0.38) | KDM4DOXTRGRM7CYP3A4AVPR2 | |
| SCHEMBL19200479 | 0.85 | KDM4D (0.37) | KDM4DOXTRGRM7CYP3A4AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | claimed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | KDM4D 2480/4885OXTR 248/4885GRM7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.